Page 1 | Search Results | Blood | American Society of Hematology

Skip Nav Destination

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Secondary Hematologic Malignancies in Patients Following Chimeric Antigen Receptor T-Cell Therapy: Aggregated Clinical Trial Data from 1542 Patients

Edward R Scheffer Cliff, Penelope Lafeuille, Sheila Diamond, Jacob Aptekar, David A Russler-Germain, Kai Rejeski, Aaron S Kesselheim

Blood (2024) 144 (Supplement 1): 2077.

https://doi.org/10.1182/blood-2024-203979

Published: 2024

Journal Articles

Using Synthetic Data Produced By Artificial Intelligence (AI) to Generate Insights for Chimeric Antigen Receptor T-Cell (CAR T-Cell) Clinical Trials

Penelope Lafeuille, Afrah Shafquat, Chao Sang, Mandis Beigi, Francesco Maura, Jacob Aptekar

Blood (2024) 144 (Supplement 1): 7484.

https://doi.org/10.1182/blood-2024-203356

Published: 2024

Journal Articles

Phosphorus Disruption Is Associated with the Incidence and Severity of Neurotoxicity Symptoms in CD19-Targeted CAR-T Cell Therapy: A Pooled Clinical Trial Analysis

Penelope Lafeuille, Sheila Diamond, Alexandru Socolov, Jacob Aptekar, Theodore Nowicki

Blood (2023) 142 (Supplement 1): 3626.

https://doi.org/10.1182/blood-2023-182138

Published: 2023

Journal Articles

Machine Learning-Based Decision Tree for Identifying and Grading Severity of Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) Based on Neurological Adverse Events in Patients Treated with CD19 CAR-T

Alexandru Socolov, Penelope Lafeuille, Sheila Diamond, Eric Yang, Francesco Maura, Jacob Aptekar, Esther Nie

Blood (2023) 142 (Supplement 1): 5018.

https://doi.org/10.1182/blood-2023-182147

Published: 2023

Journal Articles

Significant Cytokine Release Syndrome Risk Model with T-Cell Engaging Therapies

Penelope Lafeuille, William Blumentals, Claire Brulle Wohlhueter, Weixi Chen, Chao Sang, Sydney Manning, Silvy Saltzman, Jan Canvin, Susan Richard, Cris Kamperschroer, Giovanni Abbadessa, Aniketh Talwai, Caroline Der-Nigoghossian, Yahav Itzkovich, Vibhu Agarwal, Rahul Jain, Tanmay Jain, Jacob Aptekar, Stephan Grupp

Blood (2023) 142 (Supplement 1): 3629.

https://doi.org/10.1182/blood-2023-181985

Published: 2023

Journal Articles

Deriving Predictive Features of Severe CRS from Pre-Infusion Clinical Data in CAR T-Cell Therapies

Vibhu Agarwal, Jacob Aptekar, David C Fajgenbaum, Penelope Lafeuille

Blood (2022) 140 (Supplement 1): 7838–7839.

https://doi.org/10.1182/blood-2022-169287

Published: 2022

NARROW

Secondary Hematologic Malignancies in Patients Following Chimeric Antigen Receptor T-Cell Therapy: Aggregated Clinical Trial Data from 1542 Patients

Using Synthetic Data Produced By Artificial Intelligence (AI) to Generate Insights for Chimeric Antigen Receptor T-Cell (CAR T-Cell) Clinical Trials

Phosphorus Disruption Is Associated with the Incidence and Severity of Neurotoxicity Symptoms in CD19-Targeted CAR-T Cell Therapy: A Pooled Clinical Trial Analysis

Machine Learning-Based Decision Tree for Identifying and Grading Severity of Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) Based on Neurological Adverse Events in Patients Treated with CD19 CAR-T

Significant Cytokine Release Syndrome Risk Model with T-Cell Engaging Therapies

Deriving Predictive Features of Severe CRS from Pre-Infusion Clinical Data in CAR T-Cell Therapies

Email alerts

ASH Publications

American Society of Hematology

Secondary Hematologic Malignancies in Patients Following Chimeric Antigen Receptor T-Cell Therapy: Aggregated Clinical Trial Data from 1542 Patients

Using Synthetic Data Produced By Artificial Intelligence (AI) to Generate Insights for Chimeric Antigen Receptor T-Cell (CAR T-Cell) Clinical Trials

Phosphorus Disruption Is Associated with the Incidence and Severity of Neurotoxicity Symptoms in CD19-Targeted CAR-T Cell Therapy: A Pooled Clinical Trial Analysis

Machine Learning-Based Decision Tree for Identifying and Grading Severity of Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) Based on Neurological Adverse Events in Patients Treated with CD19 CAR-T

Significant Cytokine Release Syndrome Risk Model with T-Cell Engaging Therapies

Deriving Predictive Features of Severe CRS from Pre-Infusion Clinical Data in CAR T-Cell Therapies

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only